Key result
Genetic testing identifies a novel CACNA1H variant in refractory early-onset hypertension with elevated aldosterone.
Why the study?
Monogenic hereditary hypertension, such as familial hyperaldosteronism, should be suspected in patients with early-onset, refractory hypertension, elevated plasma aldosterone, and family history, but biochemical screening alone may lead to misdiagnosis.
Case Report (n=1)
Genetic testing should be considered as a complementary diagnostic tool for patients with early-onset hypertension and a family history of hypertension, even when routine biochemical markers like ARR are negative.
Extends candidate genes for early-onset hypertension to CACNA1H; hypothesis-generating and requires validation before any clinical role.
The prevalence of early-onset hypertension is rising annually and is accompanied by progressive target organ damage, contributing to a higher risk of cardiovascular mortality. In patients with early-onset hypertension characterized by refractory hypertension, elevated plasma aldosterone levels, and a family history of hypertension, monogenic hereditary hypertension, such as familial hyperaldosteronism, should be suspected, although this condition is rare. A 36-year-old male patient with hypertension fails to achieve target blood pressure despite receiving four antihypertensive medications, including a diuretic. The patient exhibited elevated plasma aldosterone levels, while the aldosterone-to-renin ratio and serum potassium levels remain within normal ranges. Further genetic analysis identifies a heterozygous variant of uncertain significance in the CACNA1H gene (nucleotide change: c.3988G > A, amino acid change: p.V1330I, chromosomal location: chr16:1260601). This genetic variant has not been previously reported. The CACNA1H gene is associated with familial hyperaldosteronism type IV. Sanger sequencing validation and family pedigree analysis were performed, confirming an autosomal dominant inheritance pattern among family members. For patients with early-onset hypertension characterized by refractory hypertension, elevated plasma aldosterone levels, and a family history of hypertension, monogenic forms of hypertension, such as familial hyperaldosteronism, should be suspected. However, For patients with negative ARR but atypical clinical manifestations of elevated aldosterone levels, exclusive reliance on common biochemical markers, such as the aldosterone-to-renin ratio and serum potassium levels, may lead to misdiagnosis or underdiagnosis. Therefore, in addition to routine biochemical markers, genetic testing should be considered a complementary diagnostic tool for patients with early-onset hypertension and a family history of hypertension.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) conducted a case report in Early-onset hypertension (n=1). CACNA1H gene variant (c.3988G > A, p.V1330I) was evaluated. A novel heterozygous variant of uncertain significance in the CACNA1H gene was identified in a 36-year-old male with refractory early-onset hypertension and elevated plasma aldosterone levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: